Back to top

Research Daily

Monday, March 12, 2018

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Visa (V), AIG (AIG) and Delta (DAL). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.

You can see all of today’s research reports here >>>

Buy-rated Visa’s shares have marginally underperformed the Zacks Financial Transaction Services industry over the last one year (+38.2% vs. +38.6%). But Visa’s key business drivers, payments volume, cross model volume and process transactions remained strong and stable across the globe.

Numerous strategic acquisitions and alliances, technology upgrades and effective marketing have paved the way for its long-term growth that have led to consistent revenue growth over the past several years. The Zacks analyst thinks Visa is well poised to gain from the growing electronic payment processing and strong international business.

A solid balance sheet ensures effective capital deployment. Visa's first-quarter fiscal 2018 results beat the estimates and were up year over year. Nevertheless, high client incentives, forex volatility are some of the headwinds.

(You can read the full research report on Visa here >>>).

Shares of AIG have underperformed the Zacks Multi-Line Insurance industry over the last three months, losing -4.1% vs. -3.6%. AIG’s fourth-quarter 2017 earnings missed the Zacks Consensus Estimate and deteriorated from the year ago quarter.

The underperformance stemmed from the negative impact of huge catastrophe losses and low premium in the General Insurance segment. However, the Zacks analyst thinks a number of asset sale and business divestitures made over the past many years have streamlined the company to some extent.

Recently, the insurance giant appointed Brian Duperreault as its new CEO with expectations of improving operations by completing ongoing restructuring initiatives and making additional changes. The company has been suffering from tough market conditions and its massive size with numerous uncorrelated businesses creating little or no synergy. Weakness in its General Insurance segment and an exposure to catastrophes continue to remain concerns.

(You can read the full research report on AIG here >>>).

Buy-rated Delta’s shares rallied +18.5% over the last one year, outperforming the Zacks Airline industry's +17.4% gain. Delta has been performing well on the unit revenue front and is expected to continue doing so in 2018 as well.

Notably, it expects total unit revenues (excluding refinery sales) to increase in the band of 2.5% to 4.5% (on a year-over-year basis) in the first quarter of 2018. The company's efforts to reward shareholders are also impressive. In 2017, it returned $2.4 billion to shareholders.

The Zacks analyst also likes the company's initiatives to reduce its debt levels. The new tax law, which reduces its corporate tax rate significantly, is anticipated to aid the company’s performance, going forward.

However, high fuel costs do not bode well for the company. Fuel price, including taxes and refinery impact, is envisioned between $2.05 and $2.10 per gallon in the first quarter of 2018.

(You can read the full research report on Delta here >>>).

Other noteworthy reports we are featuring today include Public Service Enterprise (PEG), Square (SQ) and Mohawk (MHK).

The Hottest Tech Mega-Trend of All

Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.

See Zacks' 3 Best Stocks to Play This Trend >>

Mark Vickery

Senior Editor

Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>>

Featured Reports

New Upgrades

New Downgrades

Overdependence on Emricasan Ails Conatus (CNAT)

Per the Zacks analyst, in the absence of approved products, Conatus is completely dependent on the successful development of Emricasan. Any regulatory setback could severely hamper Conatus' prospects.